Skip to main content

Table 2 Unit prices, DDDc ranges and affordability rate of surveyed drugs in each efficacy group in China from 2017 to 2020 (%)

From: Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges

ICD-11 categories of surveyed drugs

Median of unit prices (min–max)/(USD)a

Median of DDDc (min–max)/(USD)b

Urban

Rural

Rate of affordabilityc (if 5% OOPd)

Rate of affordability (if 5% OOP)

2017

2018

2019

2020

2017

2018

2019

2020

2018

2019

2020

2018

2019

2020

Endocrine, nutritional and metabolic diseases

0.02 (0.00–579.02)

0.02 (0.00–563.04)

0.05 (0.00–563.04)

0.10 (0.00–506.17)

2.10 (0.06–57.32)

2.00 (0.07–56.42)

2.43 (0.09–1464.71)

10.77 (0.07–2519.71)

15.2

17.2

18.2

15.2

15.2

16.2

Diseases of the nervous system

0.04 (0.00–3.72)

0.03 (0.00–6.43)

0.03 (0.00–6.67)

0.07 (0.00–8574.75)

2.44 (0.02–53.31)

2.62 (0.03–53.31)

2.62 (0.03–30.95)

3.59 (0.04–857.48)

21.2

21.2

22.2

18.2

18.2

20.2

Diseases of the blood or blood-forming organs

0.14 (0.00–904.18)

0.14 (0.00–850.00)

0.14 (0.00–850)

0.14 (0.00–808.82)

10.68 (0.00–5696.30)

10.29 (0.00–5355.00)

10.24 (0.00–5355.00)

10.18 (0.00–5095.59)

11.1

11.1

11.1

9.1

9.1

9.1

Diseases of the circulatory system

0.20 (0.07–0.97)

0.25 (0.07–14.70)

0.73 (0.06–3516.62)

1.35 (0.06–3516.62)

15.15 (1.27–131.81)

22.40(1.27–146.96)

29.38 (1.27–146.96)

23.41 (1.27–131.77)

2.0

4.0

9.1

1.0

1.0

8.1

Developmental anomalies

5.16 (0.00–8.58)

5.00 (0.00–7.65)

4.86 (0.00–7.02)

4.66 (0.00–7.01)

7.30 (0.06–34.18)

6.84 (0.07–35.89)

6.53 (0.08–35.89)

6.52 (0.07–32.50)

7.1

8.1

8.1

3.0

5.1

5.1

Diseases of the respiratory system

2.02 (0.02–4.02)

2.12 (0.02–4.22)

0.37 (0.02–4.22)

0.23 (0.02–3.82)

38.24 (38.26–40.21)

39.24 (36.26–42.22)

76.01 (36.26–109.80)

38.24 (28.57–69.22)

1.0

2.0

3.0

1.0

2.0

3.0

Diseases of the immune system

0.04 (0.00–0.07)

0.04 (0.00–0.07)

0.07 (0.00–75.49)

0.06 (0.00–75.49)

0.36 (0.13–0.59)

0.37 (0.13–0.62)

0.59 (0.12–63.41)

0.59 (0.11–63.41)

2.0

2.0

3.0

2.0

2.0

3.0

Total

0.11 (0.00–904.18)

0.10 (0.00–850.00)

0.13 (0.00–3516.62)

0.20 (0.00–8574.75)

6.00 (0.00–5696.30)

6.43 (0.00–5355)

7.45 (0.00–5355)

10.68 (0.00–5095.59)

59.6

65.7

74.7

49.5

52.5

64.6

  1. aUse the minimum specifications as the standards about the investigated drugs. Translated the price and took the median values as analysis objects
  2. bIn the calculations, we used the following average values: adult weight at 70 kg, children 15 kg, baby 1.5 kg; the body surface area at 1.7 m2
  3. cRate of affordability = Number of affordable drugs in each efficacy group/Number of drugs in each efficacy group × 100%. The 2017 NMBI implementation was mid-year, and to ensure accurate of data, we began analyzing affordability rates only from 2018
  4. d“OOP”: out-of-pocket expenses